bioRxiv Science⌕ Search

Biology subjects

Underhill, J.

Publications and source records attributed to Underhill, J..

2 recordsLinked to original sources

Effective sequence-to-expression prediction for membrane proteins using machine learning and computational protein design

The recombinant expression of integral membrane proteins is notoriously challenging. One way to address this challenge is via computational genotype-to-phenotype models that determine how particular sequence features correlate with protein expression levels. However, the potential of such approaches is yet to be fully realised, at least partly because so few expression datasets are available. Here, we study the sequence-to-expression relationships of a library of 12,248 variants of a specific membrane protein derived from combinatorial computational design. The major advantage of this approach lies in the controlled sequence diversity explored in design, making this new dataset directly compatible with lightweight off-the-shelf bioinformatic tools. The expression phenotype of the entire library is assessed in the widely-used recombinant host Escherichia coli. We employed a relatively small dataset of [~]2000 phenotyped sequences to train a sequence-to-expression predictor using supervised machine learning, which achieved high classification accuracy on held-out test sequences. This model was then used to infer the expression of >10,000 unmeasured sequences, and validation of the top predictions of both high and low expressers achieved 100% success rate. Using tools from explainable AI, we identified specific sequence positions and substitutions that are most important in dictating cellular expression levels. This analysis was validated by model-guided protein engineering that achieved an 8-fold increase in the purification yield of a poorly-expressing variant. Our results show that, at least for this controlled dataset, straightforward and interpretable machine learning can reveal the intrinsic sequence code for membrane protein expression.

bioengineering↗

How Varenicline Works: Identifying Critical Receptor and Ligand-based Interactions

Approved by the FDA in 2006, varenicline became the first nicotinic-based therapeutic for smoking cessation and has since been used by tens of millions of smokers worldwide. Varenicline works by targeting the 4{beta}2 nicotinic acetylcholine receptor (nAChR), the primary focus for nicotine addiction, where ligand recognition by the receptor triggers ion channel opening. While widely recognized that vareniclines development was rooted in the well-established pharmacology of cytisine, the two compounds display notably different profiles, not only at nAChRs, but also at key off-target sites such as the 5-HT3 serotonin receptor. Despite vareniclines widespread use and proven efficacy as a smoking cessation aid, our knowledge of the precise molecular mechanism underlying its action, particularly the specific receptor-ligand interactions that underpin its functional specificity, remains incomplete. Through a multidisciplinary approach that integrates complementary fields of research, this study reveals the critical receptor-ligand interactions that distinguish varenicline from related nAChR agonists, such as cytisine and nicotine. Our findings reveal previously unrecognized, critical hydrogen bonding interactions within the 4{beta}2 binding sites, specifically involving 4T139, 4T183, and {beta}2S133, that are uniquely and selectively engaged by varenicline. Of these, {beta}2S133 emerged as the pivotal determinant of vareniclines function, with substitution by valine significantly impairing the ligand efficacy. Furthermore, the design and synthesis of novel varenicline analogues shed new light into the functional importance of the ligands quinoxaline moiety, revealing that not just the presence but also the precise positioning of this hydrogen bond acceptor are critical for receptor activation by varenicline. Together, these findings uncover a previously uncharacterized interaction network essential for vareniclines function at 4{beta}2, offering a deeper and more comprehensive framework for understanding its distinct pharmacological profile while expanding our broader understanding of how ligand binding is translated into function in these receptors. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=174 SRC="FIGDIR/small/659675v1_ufig1.gif" ALT="Figure 1"> View larger version (19K): org.highwire.dtl.DTLVardef@a77e39org.highwire.dtl.DTLVardef@4fec37org.highwire.dtl.DTLVardef@11d26a2org.highwire.dtl.DTLVardef@d35640_HPS_FORMAT_FIGEXP M_FIG C_FIG

pharmacology and toxicology↗